224 related articles for article (PubMed ID: 26389667)
1. Binding of the multimodal antidepressant drug vortioxetine to the human serotonin transporter.
Andersen J; Ladefoged LK; Wang D; Kristensen TN; Bang-Andersen B; Kristensen AS; Schiøtt B; Strømgaard K
ACS Chem Neurosci; 2015 Nov; 6(11):1892-900. PubMed ID: 26389667
[TBL] [Abstract][Full Text] [Related]
2. Genetically encoded photocrosslinkers locate the high-affinity binding site of antidepressant drugs in the human serotonin transporter.
Rannversson H; Andersen J; Sørensen L; Bang-Andersen B; Park M; Huber T; Sakmar TP; Strømgaard K
Nat Commun; 2016 Apr; 7():11261. PubMed ID: 27089947
[TBL] [Abstract][Full Text] [Related]
3. Serotonin Transporter-Independent Actions of the Antidepressant Vortioxetine As Revealed Using the SERT Met172 Mouse.
Nackenoff AG; Simmler LD; Baganz NL; Pehrson AL; Sánchez C; Blakely RD
ACS Chem Neurosci; 2017 May; 8(5):1092-1100. PubMed ID: 28272863
[TBL] [Abstract][Full Text] [Related]
4. Modes and nodes explain the mechanism of action of vortioxetine, a multimodal agent (MMA): enhancing serotonin release by combining serotonin (5HT) transporter inhibition with actions at 5HT receptors (5HT1A, 5HT1B, 5HT1D, 5HT7 receptors).
Stahl SM
CNS Spectr; 2015 Apr; 20(2):93-7. PubMed ID: 25831967
[TBL] [Abstract][Full Text] [Related]
5. The rapid recovery of 5-HT cell firing induced by the antidepressant vortioxetine involves 5-HT(3) receptor antagonism.
Bétry C; Pehrson AL; Etiévant A; Ebert B; Sánchez C; Haddjeri N
Int J Neuropsychopharmacol; 2013 Jun; 16(5):1115-27. PubMed ID: 23089374
[TBL] [Abstract][Full Text] [Related]
6. Vortioxetine, a novel antidepressant with multimodal activity: review of preclinical and clinical data.
Sanchez C; Asin KE; Artigas F
Pharmacol Ther; 2015 Jan; 145():43-57. PubMed ID: 25016186
[TBL] [Abstract][Full Text] [Related]
7. Discovery of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine (Lu AA21004): a novel multimodal compound for the treatment of major depressive disorder.
Bang-Andersen B; Ruhland T; Jørgensen M; Smith G; Frederiksen K; Jensen KG; Zhong H; Nielsen SM; Hogg S; Mørk A; Stensbøl TB
J Med Chem; 2011 May; 54(9):3206-21. PubMed ID: 21486038
[TBL] [Abstract][Full Text] [Related]
8. Differentiated effects of the multimodal antidepressant vortioxetine on sleep architecture: Part 2, pharmacological interactions in rodents suggest a role of serotonin-3 receptor antagonism.
Leiser SC; Iglesias-Bregna D; Westrich L; Pehrson AL; Sanchez C
J Psychopharmacol; 2015 Oct; 29(10):1092-105. PubMed ID: 26174134
[TBL] [Abstract][Full Text] [Related]
9. Y95 and E444 interaction required for high-affinity S-citalopram binding in the human serotonin transporter.
Combs S; Kaufmann K; Field JR; Blakely RD; Meiler J
ACS Chem Neurosci; 2011 Feb; 2(2):75-81. PubMed ID: 22778858
[TBL] [Abstract][Full Text] [Related]
10. Binding of serotonin to the human serotonin transporter. Molecular modeling and experimental validation.
Celik L; Sinning S; Severinsen K; Hansen CG; Møller MS; Bols M; Wiborg O; Schiøtt B
J Am Chem Soc; 2008 Mar; 130(12):3853-65. PubMed ID: 18314975
[TBL] [Abstract][Full Text] [Related]
11. Comparative molecular field analysis using selectivity fields reveals residues in the third transmembrane helix of the serotonin transporter associated with substrate and antagonist recognition.
Walline CC; Nichols DE; Carroll FI; Barker EL
J Pharmacol Exp Ther; 2008 Jun; 325(3):791-800. PubMed ID: 18354055
[TBL] [Abstract][Full Text] [Related]
12. An overview of vortioxetine.
Schatzberg AF; Blier P; Culpepper L; Jain R; Papakostas GI; Thase ME
J Clin Psychiatry; 2014 Dec; 75(12):1411-8. PubMed ID: 25551236
[TBL] [Abstract][Full Text] [Related]
13. The binding mode of vilazodone in the human serotonin transporter elucidated by ligand docking and molecular dynamics simulations.
Zhang Y; Zheng G; Fu T; Hong J; Li F; Yao X; Xue W; Zhu F
Phys Chem Chem Phys; 2020 Mar; 22(9):5132-5144. PubMed ID: 32073004
[TBL] [Abstract][Full Text] [Related]
14. Modeling and Mutational Analysis of the Binding Mode for the Multimodal Antidepressant Drug Vortioxetine to the Human 5-HT
Ladefoged LK; Munro L; Pedersen AJ; Lummis SCR; Bang-Andersen B; Balle T; Schiøtt B; Kristensen AS
Mol Pharmacol; 2018 Dec; 94(6):1421-1434. PubMed ID: 30257860
[TBL] [Abstract][Full Text] [Related]
15. Antidepressant and anxiolytic potential of the multimodal antidepressant vortioxetine (Lu AA21004) assessed by behavioural and neurogenesis outcomes in mice.
Guilloux JP; Mendez-David I; Pehrson A; Guiard BP; Repérant C; Orvoën S; Gardier AM; Hen R; Ebert B; Miller S; Sanchez C; David DJ
Neuropharmacology; 2013 Oct; 73():147-59. PubMed ID: 23721744
[TBL] [Abstract][Full Text] [Related]
16. Binding and orientation of tricyclic antidepressants within the central substrate site of the human serotonin transporter.
Sinning S; Musgaard M; Jensen M; Severinsen K; Celik L; Koldsø H; Meyer T; Bols M; Jensen HH; Schiøtt B; Wiborg O
J Biol Chem; 2010 Mar; 285(11):8363-74. PubMed ID: 19948720
[TBL] [Abstract][Full Text] [Related]
17. Mutational mapping and modeling of the binding site for (S)-citalopram in the human serotonin transporter.
Andersen J; Olsen L; Hansen KB; Taboureau O; Jørgensen FS; Jørgensen AM; Bang-Andersen B; Egebjerg J; Strømgaard K; Kristensen AS
J Biol Chem; 2010 Jan; 285(3):2051-63. PubMed ID: 19892699
[TBL] [Abstract][Full Text] [Related]
18. Vortioxetine: A review of the pharmacology and clinical profile of the novel antidepressant.
Sowa-Kućma M; Pańczyszyn-Trzewik P; Misztak P; Jaeschke RR; Sendek K; Styczeń K; Datka W; Koperny M
Pharmacol Rep; 2017 Aug; 69(4):595-601. PubMed ID: 28499187
[TBL] [Abstract][Full Text] [Related]
19. Modes and nodes explain the mechanism of action of vortioxetine, a multimodal agent (MMA): actions at serotonin receptors may enhance downstream release of four pro-cognitive neurotransmitters.
Stahl SM
CNS Spectr; 2015 Dec; 20(6):515-9. PubMed ID: 26062986
[TBL] [Abstract][Full Text] [Related]
20. Effect of the multimodal acting antidepressant vortioxetine on rat hippocampal plasticity and recognition memory.
Bétry C; Etiévant A; Pehrson A; Sánchez C; Haddjeri N
Prog Neuropsychopharmacol Biol Psychiatry; 2015 Apr; 58():38-46. PubMed ID: 25524057
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
